Sanofi CEO defends company’s move to abandon profit guidance and boost research; In the fight against cancer, it’s boom times for radiopharmaceuticals

Taking stock of the drug industry, from the lab to the medicine chest

November 8, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Carolyn Kaster/AP STAT+ | Sanofi CEO defends company's move to abandon profit guidance and boost research Sanofi CEO Paul Hudson argued that the dramatically negative market response didn't reflect the potential rewards the plan could bring. By Andrew Joseph STAT+ | In the fight against cancer, it's boom times for radiopharmaceuticals Investors and executives are optimistic these investments will pay off not just for venture capitalists, but for cancer patients. By Allison DeAngelis STAT+ | Biotech incubator Curie.Bio graduates its first startup The startup, Forward Therapeutics, is coming out of the incubator with three drug candidates for chronic inflammatory disorders. By Allison DeAngelis Darron Cummings/AP Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound The obesity approval for tirzepatide introduces stiff competition for Novo Nordisk, which has had shortages of its obesity treatment Wegovy. By Elaine Chen and Damian Garde

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser